About 1 results.

肝病创新基因疗法获FDA突破性疗法认定

肝病创新基因疗法获FDA突破性疗法认定
2017-06-05 领先的RNAi治疗公司Alnylam Pharmaceuticals近日宣布,其在研新药givosiran获得了FDA颁发的突破性疗法认定。Givosiran是一种针对氨基乙酰丙酸合酶1(aminolevulinic acid synthase 1,ALAS1)的RNAi疗法,用于预防急性肝卟啉症(
http://www.chemcd.com/news/37984.html